Search Results

Caring for patients with acute myeloid leukemia (AML) depends on many factors and can vary as much as the patients themselves.

Genetic counselors—as members of the cancer care team—can help patients better understand their cancer diagnosis, make informed treatment decisions, and navigate the financial costs of testing.

One serious, unwanted side effect of the COVID-19 pandemic is the potential for substantial consequences for cancer outcomes due to delayed access to cancer diagnosis and treatment. Hear from Dr. Debra Patt, the author of a study which detected a substantial decrease (among American seniors) in cancer screenings, visits, therapy, and surgeries.

In this episode, we talk with an oncology program manager and member of the Financial Advocacy Network Advisory Committee about the great need this robust resource fills in helping relieve financial toxicity, so patients can focus on their cancer care.

In this episode, we talk with an experienced cancer center information technology (IT) professional about how the role of the IT professional in quality, patient-centered cancer care delivery and what lies ahead.

We'll discuss the telehealth regulatory and policy changes enacted during the COVID-19 pandemic, what may change in 2021, and what’s likely to remain the same regarding the reimbursement of remote care.

Learn how genetic healthcare services have adapted to virtual care delivery, and what challenges face its widespread use after the COVID-19 pandemic is over.

On this episode of CANCER BUZZ, we discuss how healthcare providers and policymakers can work together to pave the future of telehealth beyond the current public health emergency.

Envision a day that cancer clinicians can ask an app to advise on immuno-oncology (IO) treatment options for a patient. That day may not be far off.

Learn how cancer programs can quickly and securely establish telemedicine platforms to continue delivering quality care during the COVID-19 pandemic.

In the current oncology clinical trials landscape, many barriers remain to clinical trial enrollment that affect both the oncologist and the patient. Among these are trial locations, strict eligibility requirements, insufficient resources to support appropriate clinical trial education and screening, as well as patient and provider attitudes about trials.

The paradigm-changing advancements accompanying immunotherapy for cancer continue to require innovation in care delivery. Telehealth is a natural innovation partner for immuno-oncology when applied to patient-reported outcomes, provider education, and clinical trial enrollment.